期刊
DIABETES OBESITY & METABOLISM
卷 13, 期 6, 页码 490-497出版社
WILEY
DOI: 10.1111/j.1463-1326.2010.01353.x
关键词
antiobesity drug; behavioural factors; clinical trial; cost-effectiveness; medicines management; obesity; obesity therapy; pathophysiological sequelae of obesity; pharmaceutical interventions; public health; regulatory guidance
The prevalence of obesity, a major risk factor for many chronic diseases, has risen in most developed countries over the past several decades. The economic burden for both public and private health care systems is substantial. Although certain non-pharmaceutical interventions have been proven efficacious in specific populations, the lack of scalability has caused many of these programmes to fail in sustainably decreasing the percent of patients who are overweight or obese. The benefits of other interventions, such as pharmaceutical agents, medical devices and surgery, should therefore be carefully considered: this article focuses on the first of these strategies. Various pharmaceutical products have been plagued with safety concerns or patient non-adherence because of unpleasant side effects. Therefore, the need for additional antiobesity drugs that are both safe and effective is considerable. This article discusses the regulatory landscape for the development of new antiobesity compounds in the United States and Europe and considers the ramifications of greater or lesser regulatory burdens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据